vs

Side-by-side financial comparison of MEDIFAST INC (MED) and Planet Labs PBC (PL). Click either name above to swap in a different company.

Planet Labs PBC is the larger business by last-quarter revenue ($81.3M vs $75.1M, roughly 1.1× MEDIFAST INC). On growth, Planet Labs PBC posted the faster year-over-year revenue change (32.6% vs -36.9%). Planet Labs PBC produced more free cash flow last quarter ($1.9M vs $-6.6M). Over the past eight quarters, Planet Labs PBC's revenue compounded faster (17.5% CAGR vs -34.4%).

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

Planet Labs PBC, known as "Planet.", is a publicly traded American Earth imaging company based in San Francisco, California. Their goal is to image the entirety of the Earth daily to monitor changes and pinpoint trends.

MED vs PL — Head-to-Head

Bigger by revenue
PL
PL
1.1× larger
PL
$81.3M
$75.1M
MED
Growing faster (revenue YoY)
PL
PL
+69.5% gap
PL
32.6%
-36.9%
MED
More free cash flow
PL
PL
$8.5M more FCF
PL
$1.9M
$-6.6M
MED
Faster 2-yr revenue CAGR
PL
PL
Annualised
PL
17.5%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
MED
MED
PL
PL
Revenue
$75.1M
$81.3M
Net Profit
$-59.2M
Gross Margin
69.4%
57.3%
Operating Margin
-10.4%
-22.6%
Net Margin
-72.8%
Revenue YoY
-36.9%
32.6%
Net Profit YoY
-194.7%
EPS (diluted)
$-1.64
$-0.19

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MED
MED
PL
PL
Q4 25
$75.1M
$81.3M
Q3 25
$89.4M
$73.4M
Q2 25
$105.6M
$66.3M
Q1 25
$115.7M
$61.6M
Q4 24
$119.0M
$61.3M
Q3 24
$140.2M
$61.1M
Q2 24
$168.6M
$60.4M
Q1 24
$174.7M
$58.9M
Net Profit
MED
MED
PL
PL
Q4 25
$-59.2M
Q3 25
$-2.3M
$-22.6M
Q2 25
$2.5M
$-12.6M
Q1 25
$-772.0K
$-35.2M
Q4 24
$-20.1M
Q3 24
$1.1M
$-38.7M
Q2 24
$-8.2M
$-29.3M
Q1 24
$8.3M
$-30.1M
Gross Margin
MED
MED
PL
PL
Q4 25
69.4%
57.3%
Q3 25
69.5%
57.6%
Q2 25
72.6%
55.2%
Q1 25
72.8%
62.1%
Q4 24
74.1%
61.2%
Q3 24
75.4%
52.9%
Q2 24
73.2%
52.4%
Q1 24
72.8%
55.2%
Operating Margin
MED
MED
PL
PL
Q4 25
-10.4%
-22.6%
Q3 25
-4.6%
-24.5%
Q2 25
-1.0%
-34.4%
Q1 25
-1.1%
-31.5%
Q4 24
0.6%
-36.9%
Q3 24
1.5%
-64.8%
Q2 24
-4.7%
-57.2%
Q1 24
4.5%
-57.6%
Net Margin
MED
MED
PL
PL
Q4 25
-72.8%
Q3 25
-2.5%
-30.8%
Q2 25
2.3%
-19.1%
Q1 25
-0.7%
-57.1%
Q4 24
-32.8%
Q3 24
0.8%
-63.3%
Q2 24
-4.8%
-48.5%
Q1 24
4.8%
-51.1%
EPS (diluted)
MED
MED
PL
PL
Q4 25
$-1.64
$-0.19
Q3 25
$-0.21
$-0.07
Q2 25
$0.22
$-0.04
Q1 25
$-0.07
$-0.12
Q4 24
$0.08
$-0.07
Q3 24
$0.10
$-0.13
Q2 24
$-0.75
$-0.10
Q1 24
$0.76
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MED
MED
PL
PL
Cash + ST InvestmentsLiquidity on hand
$167.3M
$443.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$198.9M
$349.6M
Total Assets
$248.0M
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MED
MED
PL
PL
Q4 25
$167.3M
$443.3M
Q3 25
$173.5M
$181.1M
Q2 25
$162.7M
$133.5M
Q1 25
$164.6M
$118.0M
Q4 24
$162.3M
$139.0M
Q3 24
$170.0M
$148.3M
Q2 24
$163.5M
$107.4M
Q1 24
$156.4M
$83.9M
Stockholders' Equity
MED
MED
PL
PL
Q4 25
$198.9M
$349.6M
Q3 25
$214.7M
$435.7M
Q2 25
$216.0M
$444.8M
Q1 25
$211.0M
$441.3M
Q4 24
$210.1M
$464.6M
Q3 24
$207.3M
$473.2M
Q2 24
$205.3M
$500.3M
Q1 24
$211.0M
$518.0M
Total Assets
MED
MED
PL
PL
Q4 25
$248.0M
$1.1B
Q3 25
$268.2M
$696.4M
Q2 25
$269.3M
$658.4M
Q1 25
$280.0M
$633.8M
Q4 24
$284.2M
$630.8M
Q3 24
$291.2M
$658.4M
Q2 24
$293.5M
$674.6M
Q1 24
$302.8M
$702.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MED
MED
PL
PL
Operating Cash FlowLast quarter
$-5.3M
$28.6M
Free Cash FlowOCF − Capex
$-6.6M
$1.9M
FCF MarginFCF / Revenue
-8.8%
2.3%
Capex IntensityCapex / Revenue
1.8%
32.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.2M
$40.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MED
MED
PL
PL
Q4 25
$-5.3M
$28.6M
Q3 25
$12.1M
$67.8M
Q2 25
$-3.4M
$17.3M
Q1 25
$3.4M
$-6.3M
Q4 24
$-4.9M
$4.1M
Q3 24
$9.1M
$-7.9M
Q2 24
$13.1M
$-4.3M
Q1 24
$7.3M
$-6.8M
Free Cash Flow
MED
MED
PL
PL
Q4 25
$-6.6M
$1.9M
Q3 25
$10.8M
$47.5M
Q2 25
$-4.8M
$9.2M
Q1 25
$1.9M
$-17.9M
Q4 24
$-7.2M
$-3.6M
Q3 24
$7.7M
$-23.0M
Q2 24
$11.1M
$-14.2M
Q1 24
$5.4M
$-15.7M
FCF Margin
MED
MED
PL
PL
Q4 25
-8.8%
2.3%
Q3 25
12.0%
64.7%
Q2 25
-4.5%
13.9%
Q1 25
1.6%
-29.1%
Q4 24
-6.1%
-5.8%
Q3 24
5.5%
-37.6%
Q2 24
6.6%
-23.6%
Q1 24
3.1%
-26.7%
Capex Intensity
MED
MED
PL
PL
Q4 25
1.8%
32.9%
Q3 25
1.5%
27.6%
Q2 25
1.3%
12.3%
Q1 25
1.3%
18.9%
Q4 24
1.9%
12.5%
Q3 24
1.0%
24.8%
Q2 24
1.1%
16.4%
Q1 24
1.1%
15.1%
Cash Conversion
MED
MED
PL
PL
Q4 25
Q3 25
Q2 25
-1.36×
Q1 25
Q4 24
Q3 24
8.04×
Q2 24
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MED
MED

Segment breakdown not available.

PL
PL

Defense And Intelligence$49.4M61%
Civil Government$18.8M23%
Commercial$13.1M16%

Related Comparisons